ABSTRACT. Pituitary, a critical component in the neuroendocrine system, plays an indispensable role in the regulation of body growth. The transcriptional factor ZBTB20 is widely expressed in brain tissues and participates in hippocampal development; however, the detailed molecular mechanism remains unknown. Therefore, the aim of this study was to investigate the effect of ZBTB20 on mouse pituitary development and related mechanisms in ZBTB20 gene knockout mice. The expressional profiles of ZBTB20 in various neuroendocrinal cells during the different developmental stages (from E10 to P0) were described by immunofluorescence staining. A ZBTB20 gene knockout mouse model was then generated. Real-time polymerase chain reaction and western blotting assays were used to detect the levels of five hormones: growth hormone (GH), prolactin (PRL), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroidstimulating hormone (TSH). ZBTB20 protein expression was identified from E14 until birth. A majority of the pituitary endocrinal cells were ZBTB20-positive. In ZBTB20 knockout mice, the level of GH decreased by half and PRL expression was eliminated. No significant change was observed in the other three hormones (LH, FSH, and TSH). ZBTB20, an important transcriptional factor in pituitary development, is mainly responsible for the 17623 ZBTB20 regulates pituitary development ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (4): 17622-17629 (2015) terminal differentiation of prolactin-secreting cells, thereby regulating the secretion of the pituitary hormones.
INTRODUCTION
The pituitary, an indispensable component of the neuroendocrinological system, maintains the body development and homeostasis by facilitating communications between the hypothalamus and peripheral target organs, thereby playing an important role in body development and metabolism. The normal development and function of pituitary is dependent on various signaling pathways and transcriptional factors, all of which may interfere with development and interrupt endocrinal homeostasis (Franceschi et al., 2011; Baranowski and Hogler, 2012) . Recent progress in genetic manipulation of animals has helped us gain more knowledge regarding the role of mutations and transcriptional factors in pituitary development; however, the molecular mechanism of this process remains unknown (Nanbu-Wakao et al., 2000) . Current research is focused on two major pathways that have been postulated to affect pituitary development: the proliferation and differentiation of stem cells in the pituitary, and the proliferation of differentiated cells. Different endocrinal cell groups have been reported to regulate cellular proliferation and development during different stages, with the most important regulatory functions being derived from pituitary hormones (Wu et al., 2003; Cabrera et al., 2013) . Scholars have gained some knowledge about the regulation of pituitary development; however, the exact mechanism of this process remains unclear. As even a single change in known signaling molecules and transcriptional factors can induce various phenotype and hormone level variations, a greater number of pituitary development-related genes must be investigated further (Reynaud et al., 2011) . Previous in vivo studies have demonstrated that the ZBTB20 transcriptional factor, expressed in the pituitary gland, plays a critical role in mouse development (Shillingford et al., 2003) . In this study, the physiological role of the ZBTB20 transcriptional factor in pituitary development was further investigated in an attempt to gain further knowledge of the molecular mechanisms underlying pituitary growth, and to provide a theoretical basis for further studies regarding hypopituitarism.
MATERIAL AND METHODS

Animals
ZBTB20 gene knockout mice were generated in-house using C57/BL6 mice. Normal C57/ BL6 mice were used as controls. The experimental protocol was pre-approved by the Animal Ethics Committee of Shandong Provincial Hospital.
Immunofluorescence assays
Mouse pituitary tissues were extracted, fixed, and embedded in paraffin. The embedded tissues were sectioned, dewaxed, and subjected to antigen retrieval using hot citric acid buffer or EDTA buffer (according to the requirements of different cytoplasmic/nuclear antigens). Endogenous peroxidase activity was quenched by 3% hydrogen peroxide (v/v). Non-specific binding was blocked by 50 μL fetal bovine serum for 1 h. The sections were incubated overnight with primary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA); subsequently, the sections were incubated with a biotin-labeled secondary antibody (Beyotime Biotechnology Inc., Beijing, China). The signals were developed with horseradish peroxidase (Boster Biologics, Pleasanton, CA, USA). The sections were incubated with a fluorescent dye, counterstained with DAPI in the dark, and the images were captured under an inverted fluorescent microscope (Olympus, Tokyo, Japan).
A total of five fields were randomly selected from each of the five slices. The staining score was described as (1) positive rate score + (2) intensity score. The positive rate score was the category of positive cells (%) in a field, filed as: 0, <5%; 1, 6-25%; 2, 26-50%; 3, 51-75%; and 4, >75%. The intensity score was as follows: 0, no color; 1, light yellow; 2, yellow-brown; and 3, dark brown. The final staining score was categorized as: negative (-), 0; weak positive (+), 1-2; positive (++), 3-4; and strong positive (+++), 5-7.
Double-immunofluorescence labeling
Pituitary tissue sections were processed as described in the previous section. The slides were subjected to peroxidase quenching, gently washed with PBS, and subsequently incubated overnight with dual-primary antibodies. Two types of secondary antibodies with CY3 or Hoechst 33258 dyes were sequentially added for biotin incubation. The images were captured under a fluorescence microscope.
Real-time reverse transcriptase-polymerase chain reaction (PCR)
Pituitary tissues (0.1 g) were added to 0.1 mL TRIzol (Invitrogen, Carlsbad, CA, USA) for total RNA extraction, according to the instructions of the manufacturer. The extracted RNA (2 μg) was used as the template for the synthesis of cDNA by in vitro reverse transcription. The PCR mixture was composed of 2 μL cDNA and the Platinum SYBR Green qPCR SuperMix (Invitrogen). The reaction conditions were set as follows: pre-denaturation at 95°C for 5 min, followed by 30 cycles of denaturation at 94°C for 30 s, annealing at 60°C for 30 s, and extension at 72°C for 60 s. The PCR products were separated by agarose gel electrophoresis using a 1% gel. The images were normalized against the 18s rRNA, which was used as an internal reference control. Semiquantitative analysis was performed using integrated optical density for the calculation of relative expression levels. Sequences of primers used are listed in Table 1 .
Forward primer
Reverse primer
5'-GACC ACTCGC ATTCCTTT-3' 5'-GGC ATTGTGAG AC ATCCC-3' 18s RNA 5'-TCAGCGTG AAGATGGCTTCG-3' 5'-TCAGATCTGGAAGGGGAAGGAA-3' Table 1 . Primers for real-time PCR. GH = growth hormone; PRL = prolactin; LH = luteinizing hormone; FSH = follicle-stimulating hormone; TSH = thyroidstimulating hormone.
Western blot
Total proteins were extracted from the pituitary using a lysis buffer, and separated via sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The separated proteins were transferred to a polyvinylidene difluoride (PVDF) membrane using a semi-dry method (BioRad, Hercules, CA, USA). The membrane was then incubated overnight with primary antibodies against growth hormone (GH), prolactin (PRL), luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and ZBTB20 (1:500; Santa Cruz Biotechnology). The membrane was then incubated with a horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:1000; Beyotime Biotechnology) for 1 h. The membrane was then developed by electrochemiluminescence (ECL). The optical density was analyzed using an imaging software (ImageQuant TL, GE Healthcare, Pittsburgh, PA, USA).
Statistical analysis
All data were analyzed using the SPSS 21.0 software package (IBM, Armonk, NY, USA). Data fitted with normal distribution are reported as means ± standard deviation (SD). Data that did not fit normal distribution are reported as the median and quartile values. Between-group comparisons of parametric data were performed using the LSD test, while the non-parametric data were compared by Kruskal-Wallis H-test (for multiple groups) or Mann-Whitney U-test (for two groups). A statistical significance was defined when P < 0.05.
RESULTS
Expressional profiles of ZBTB20 in pituitary at different stages
Immunofluorescence was used to describe the expression of ZBTB20 proteins during the different developmental stages (from E10 to P0). The ZBTB20 protein was initially identified in E14 pituitary. The number of ZBTB20-positive cells increased significantly from E15 and E16 until birth. Both anterior and posterior pituitary lobes contained large amounts of ZBTB20 ( Figure 1 and Table 2 ). 
Distribution of ZBTB20 in different pituitary endocrine cells
We further tested the expression of ZBTB20 in different pituitary endocrinal cells (eosinophilic, basophilic, and chromophobe cells). Immunofluorescence staining (Figure 2 and Table  3 ) revealed the existence of ZBTB20 in most endocrine cells, as supported by the co-localization of ZBTB20 and different hormones, including GH, PRL, LH, FSH, TSH, and adrenocorticotrophic hormone (ACTH). Table 2 . ZBTB20 expression profiles.
Weak positive (+); positive (++); strong positive (+++) cells. Table 3 . ZBTB20 expression profiles across various endocrinal cell groups. GH = growth hormone; PRL = prolactin; LH = luteinizing hormone; FSH = follicle-stimulating hormone; TSH = thyroidstimulating hormone.
Real-time PCR
Real-time PCR was performed in ZBTB20 gene knockout (KO) mice to measure the mRNA levels of different hormones in pituitary cells. As shown in Table 4 , hardly any PRL mRNA was detected in KO mice, and GH mRNA expression was only about half of that seen in control animals. However, the mRNA level of the other three hormones, did not differ significantly in the pituitary. Table 4 . mRNA levels of pituitary cells releasing hormones. GH = growth hormone; PRL = prolactin; LH = luteinizing hormone; FSH = follicle-stimulating hormone; TSH = thyroidstimulating hormone.
Protein levels of released hormones
The protein levels of all five pituitary-derived hormones were also evaluated by western blot. The results obtained were consistent with those of mRNA ( Table 5 . Protein levels of pituitary-releasing hormones. GH = growth hormone; PRL = prolactin; LH = luteinizing hormone; FSH = follicle-stimulating hormone; TSH = thyroidstimulating hormone.
DISCUSSION
The pituitary, a major component of the neuroendocrine system, communicates between the hypothalamus and peripheral target organs, and plays an important role in ensuring normal growth and metabolism in the body. As it involves complex processes, the human body development can be severely compromised by abnormal development of the pituitary (Dateki et al., 2010; Qi Wei et al., 2011; Skarnes et al., 2011) . In this study, the pituitary development-related transcriptional factor ZBTB20 was shown to express from E14 stage until birth. This was abundantly distributed in both the anterior and posterior regions of the pituitary even in adult mice. At E15 or E16, the number of ZBTB20-positive cells increased significantly. As this is also the differentiation time of GH and PRL, it can be deduced that ZBTB20 expression occurred before the differentiation of these two hormones, suggesting the potential participation of ZBTB20 in this process, and in maintaining normal morphology and function of pituitary (El Chehadeh et al., 2010; Di Iorgi et al., 2012b; Harrington and Palmert, 2012) .
